Adherence and AHA initiation during 12 months of follow-up
| Canagliflozin 300 mg(n=750) | Any dose of GLP-1 receptor agonist (n=2417) | p value | |
| Proportion of days covered by index medication, n (%) | 750 (100.0) | 2417 (100.0) | |
| Proportion of days covered among all patients, mean (SD) | 0.67 (0.29) | 0.59 (0.31) | <0.0001* |
| Proportion of days covered among all patients, median | 0.79 | 0.66 | |
| Proportion of days covered <80% (non-adherent), n (%) | 394 (52.5) | 1511 (62.5) | <0.0001* |
| Proportion of days covered ≥80% (adherent), n (%) | 356 (47.5) | 906 (37.5) | |
| Any new AHA, n (%) | 244 (32.6) | 800 (33.1) | 0.801 |
| Time to new AHA from index date (days), mean (SD) | 158 (110) | 160 (109) | 0.751 |
| Time to new AHA from index date (days), median | 146 | 148 | |
| Discontinuation of the index medication, n (%) | 372 (49.6) | 1388 (57.4) | <0.0001* |
| Time to discontinuation (days), mean (SD) | 187 (120) | 163 (120) | 0.001* |
| Time to discontinuation (days), median | 182 | 127 | |
| Any switching of the index medication, n (%) | 253 (33.8) | 928 (38.4) | 0.023* |
| Time to the first switching (days), mean (SD) | 198 (103) | 176 (96) | 0.002* |
| Time to the first switching (days), median | 224 | 166 | |
| Newly started AHAs after switching, n (%)† | |||
| SGLT2 inhibitors | 20 (2.7) | 68 (2.8) | 0.835 |
| GLP-1 receptor agonists | 27 (3.6) | 85 (3.5) | 0.950 |
| Sulfonylureas | 62 (8.2) | 181 (7.5) | 0.523 |
| Biguanides (metformin HCl) | 116 (15.5) | 435 (18.0) | 0.115 |
| DPP-4 inhibitors | 67 (8.9) | 104 (4.3) | <0.0001* |
| Thiazolidinediones | 12 (1.6) | 43 (1.8) | 0.754 |
| Insulin | 31 (4.1) | 188 (7.8) | 0.001* |
| Amylin analogs (pramlintide acetate) | 0 (0.0) | 0 (0.0) | – |
| Alpha-glucosidase inhibitors | 0 (0.0) | 0 (0.0) | – |
| Meglitinide analogs | ≤10 | ≤10 | 0.940 |
| Others‡ | 0.5 (0.1) | ≤10 | 0.875 |
*Statistically significant.
†The medication classes may not be mutually exclusive because patients may have filled prescriptions in more than one class on the same day.
‡Dextrose, bromocriptine, diazoxide, glucagon, glucagon (rDNA), glucagon HCl (rDNA), glucose-vitamin C, mifepristone (hyperglycemia), metformin HCl—dietary management product, aldose reductase inhibitors.
AHA, antihyperglycemic agent; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT2, sodium glucose co-transporter 2.